The internally truncated LRP5 receptor presents a therapeutic target in breast cancer.

ABSTRACT:

Background

Breast cancer is a common malignant disease, which may be caused by a number of genes deregulated by genomic or epigenomic events. Deregulated WNT/beta-catenin signaling with accumulation of beta-catenin is common in breast tumors, but mutations in WNT signaling pathway components have been rare. An aberrantly spliced internally truncated LRP5 receptor (LRP5Delta666-809, LRP5Delta) was shown recently to be resistant to DKK1 inhibition, and was required for beta-catenin accumulation in hyperparathyroid tumors and parathyroid tumor growth.

Methodology/principal findings

Here we show, by reverse transcription PCR and Western blot analysis, that LRP5Delta is frequently expressed in breast tumors of different cancer stage (58-100%), including carcinoma in situ and meta

SUBMITTER: Bjorklund P 

PROVIDER: S-EPMC2627768 | biostudies-literature | 2009

REPOSITORIES: biostudies-literature